Exploring new approaches to treat mesothelioma
Official title: New Preclinical and Clinical Approaches to Mesothelioma, an Archetypal Inflammatory Tumor
Run by IRCCS Ospedale San Raffaele · NCT06536179 · Data updated 2026-11-12
This study is trying to see if targeting certain proteins can help improve treatment and immune response for people with mesothelioma.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | IRCCS Ospedale San Raffaele Academic / other |
| Locations | 2 sites (Naples, Campania and 1 other locations) |
| Status | Recruiting |
| Started | July 25, 2024 |
| Main results expected | July 25, 2025 |
| Study ends | January 25, 2027 |
| Registry record updated | August 2, 2024 |
| Trial ID | NCT06536179 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a clinical suspicion or confirmed diagnosis of pleural mesothelioma who are candidates for surgical intervention.
✕Probably not a fit
Patients without pleural mesothelioma or those whose diagnosis does not confirm clinical suspicion may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the roles of HMGB1 and CXCR4 in mesothelioma treatment and metastasis. It involves collaboration between two major cancer research institutions in Italy, focusing on how targeting these pathways can inhibit tumor progression and enhance anti-tumor immunity. The study will collect additional blood samples during routine clinical practice to support its findings. By understanding these mechanisms, the research hopes to improve therapeutic outcomes for patients with mesothelioma.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies that significantly improve treatment outcomes for mesothelioma patients.
How similar studies have gone: While targeting HMGB1 and CXCR4 in cancer treatment is a promising approach, the specific combination and methodology in this study may be novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Mesothelioma: Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma. * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. * Capacity to comprehend the study nature and provide autonomously informed consent. Control Group patients: * Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious). * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. * Ability to understand the study nature and provide autonomously informed consent. If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study. Exclusion Criteria: * Lack of biopsy material. * pregnancy. * Unwillingness to sign the Informed Consent.
Where it's running
-
Istituto Nazionale Tumori IRCCS Fondazione G.Pascale
Naples, Campania, Italy Recruiting -
IRCCS San Raffaele
Milan, Lombardy, Italy Recruiting
Study contacts
- Principal investigator: Marco Bianchi, Professor — IRCCS Ospedale San Raffaele
- Study coordinator: Massimo Crippa, PhD
- Email: crippa.massimo@hsr.it
- Phone: 02-26434833
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Partial pleurectomy to relieve symptoms from unresectable pleural mesothelioma.
The team will try a limited partial pleurectomy and decortication to reduce chest symptoms and improve quality of life for people with epithelioid pleural mesothelioma that cannot be completely removed.
-
Treatment with Sacituzumab Govitecan for Mesothelioma
This study tests if a new treatment called sacituzumab govitecan can help people with mesothelioma who have already tried other therapies feel better and manage their disease.
-
Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy
This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.
-
SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors
This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.
-
Two-part Phase 1/2 test of ODM-212 combined with other cancer treatments
This trial tests the oral drug ODM-212, given alone or with approved medicines, to see if it helps adults with advanced mesothelioma, pancreatic cancer, or non-small cell lung cancer.
-
IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors
This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.